← Back to Search

Other

Orforglipron for Obesity

Phase 3
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Acute or chronic hepatitis
History of acute or chronic pancreatitis
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Pivotal Trial

Summary

"This trial aims to test how well orforglipron helps people to keep off weight they have lost, and whether it is safe to use for this purpose."

Who is the study for?
This trial is for individuals who are overweight or have obesity with related health issues. It's designed to see if they can maintain weight loss after initial reduction. Specific eligibility details aren't provided, but typically participants must meet certain health criteria and not be taking conflicting medications.
What is being tested?
The study is testing the effectiveness of a drug called Orforglipron in helping people keep off weight they've already lost. Participants will either receive Orforglipron or a placebo (a substance with no active drug) to compare results.
What are the potential side effects?
While specific side effects of Orforglipron are not listed here, common ones for weight maintenance drugs may include gastrointestinal issues, headaches, dizziness, and potential changes in mood or sleep patterns.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have hepatitis.
Select...
I have a history of pancreatitis.
Select...
I have a history of diabetes or severe diabetic complications.
Select...
I have had or am planning to have surgery for weight loss.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: OrforglipronExperimental Treatment1 Intervention
Participants will receive orforglipron orally
Group II: PlaceboPlacebo Group1 Intervention
Participants will receive placebo orally
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Orforglipron
2024
Completed Phase 1
~80

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,673 Previous Clinical Trials
3,463,573 Total Patients Enrolled
70 Trials studying Obesity
55,347 Patients Enrolled for Obesity
Study DirectorEli Lilly and Company
1,387 Previous Clinical Trials
426,478 Total Patients Enrolled
52 Trials studying Obesity
34,889 Patients Enrolled for Obesity
~200 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top